X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MERCK LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA MERCK LTD DISHMAN PHARMA/
MERCK LTD
 
P/E (TTM) x 25.1 34.2 73.5% View Chart
P/BV x 3.3 3.8 87.6% View Chart
Dividend Yield % 0.7 0.7 89.8%  

Financials

 DISHMAN PHARMA   MERCK LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MERCK LTD
Dec-16
DISHMAN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3741,060 35.3%   
Low Rs129623 20.7%   
Sales per share (Unadj.) Rs197.8632.4 31.3%  
Earnings per share (Unadj.) Rs21.245.7 46.4%  
Cash flow per share (Unadj.) Rs34.762.3 55.7%  
Dividends per share (Unadj.) Rs2.0011.00 18.2%  
Dividend yield (eoy) %0.81.3 60.8%  
Book value per share (Unadj.) Rs179.9388.8 46.3%  
Shares outstanding (eoy) m80.6916.60 486.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 95.6%   
Avg P/E ratio x11.918.4 64.5%  
P/CF ratio (eoy) x7.213.5 53.7%  
Price / Book Value ratio x1.42.2 64.6%  
Dividend payout %9.424.1 39.2%   
Avg Mkt Cap Rs m20,30613,969 145.4%   
No. of employees `0000.81.6 52.4%   
Total wages/salary Rs m5,3551,487 360.2%   
Avg. sales/employee Rs Th19,252.76,631.9 290.3%   
Avg. wages/employee Rs Th6,459.5939.2 687.8%   
Avg. net profit/employee Rs Th2,064.1479.4 430.5%   
INCOME DATA
Net Sales Rs m15,96110,498 152.0%  
Other income Rs m265242 109.5%   
Total revenues Rs m16,22610,741 151.1%   
Gross profit Rs m4,1031,135 361.4%  
Depreciation Rs m1,091276 395.9%   
Interest Rs m9440-   
Profit before tax Rs m2,3341,102 211.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624343 181.6%   
Profit after tax Rs m1,711759 225.5%  
Gross profit margin %25.710.8 237.7%  
Effective tax rate %26.731.1 85.8%   
Net profit margin %10.77.2 148.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,410 171.9%   
Current liabilities Rs m9,5178,828 107.8%   
Net working cap to sales %9.4-23.0 -40.8%  
Current ratio x1.20.7 159.5%  
Inventory Days Days11058 191.6%  
Debtors Days Days3538 90.8%  
Net fixed assets Rs m16,3041,406 1,159.3%   
Share capital Rs m161166 97.2%   
"Free" reserves Rs m12,9076,286 205.3%   
Net worth Rs m14,5166,455 224.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8058,828 337.6%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 45.0%   
Return on assets %8.98.6 103.6%  
Return on equity %11.811.8 100.3%  
Return on capital %17.517.1 102.7%  
Exports to sales %24.88.3 299.3%   
Imports to sales %3.721.0 17.8%   
Exports (fob) Rs m3,956869 455.0%   
Imports (cif) Rs m5962,209 27.0%   
Fx inflow Rs m4,952959 516.4%   
Fx outflow Rs m6972,612 26.7%   
Net fx Rs m4,255-1,653 -257.4%   
CASH FLOW
From Operations Rs m2,7861,070 260.3%  
From Investments Rs m-1,529-750 203.9%  
From Financial Activity Rs m-941-150 628.2%  
Net Cashflow Rs m316171 185.1%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.7 18.2 20.3%  
FIIs % 12.7 1.0 1,270.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 29.1 75.9%  
Shareholders   46,261 28,591 161.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS